Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPTOR Trial: Consolidation Radiation + Immunotherapy for ES-SCLC
NCT04402788Phase 3Suspended
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival up to 6 years and Overall Survival up to 6 years. Started Jan 2021; status: suspended.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04402788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402788.